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thine therapy. The most frequent indication for therapy re-
ported in CAP was treatment of documented apnea, fol-
lowed by the facilitation of the removal of an endotracheal 
tube. Only about 20% of the neonatologists in the trial start-
ed caffeine for the prevention of apnea and the findings of 
CAP cannot automatically be extrapolated to an exclusive 
prophylactic indication. However, recent data suggest that 
the administration of prophylactic methylxanthine by neo-
natologists is now common practice.  © 2014 S. Karger AG, Basel 
 Pharmacological Studies in Children 
 Despite the introduction of new legislation in the Eu-
ropean Union in 2007 aimed at increasing the amount of 
pediatric data on medicinal products, off-label drug use 
in pedriatric patients in hospitals is still common  [1] . Ac-
cording to a nationwide population-based investigation 
of pediatric drug use at Swedish hospitals, the percentage 
of unlicensed and off-label drug use, i.e. 7.4 and 57%, re-
spectively, is highest in neonates  [1] ; similar reports have 
also emerged in other countries  [2, 3] . Neonates and es-
pecially preterm infants are particularly vulnerable be-
cause of their small body size and immature body organs 
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 Abstract 
 Caffeine, a methylxanthine and nonspecific inhibitor of
adenosine receptors, is an example of a drug that has been 
in use for more than 40 years. It is one of the most common-
ly prescribed drugs in neonatal medicine. However, until 
2006, it had only a few relatively small and short-term studies 
supporting its use. It is thanks to the efforts of Barbara 
Schmidt and the Caffeine for Apnea of Prematurity (CAP) Tri-
al Group that we now have high-quality and reliable data not 
only on short-term but also long-term outcomes of caffeine 
use for apnea of prematurity. CAP was an international, mul-
ticenter, placebo-controlled randomized trial designed to 
determine whether survival without neurodevelopmental 
disability at a corrected age of 18 months is improved if ap-
nea of prematurity is managed without methylxanthines in 
infants at a high risk of apneic attacks. CAP was kept simple 
and pragmatic in order to allow for maximum generaliz-
ability and applicability. Infants with birth weights of 500–
1,250 g were enrolled during the first 10 days of life if their 
clinicians considered them to be candidates for methylxan-
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 [4] . Neonatal clinical drug trials of a high standard and 
with sufficient sample sizes to allow firm conclusions are 
needed, not only for the investigation of new and future 
drugs but also for older products that are widely used in 
clinical practice without sufficient data on efficacy and 
safety, e.g. inhaled steroids for the prevention and/or 
treatment of bronchopulmonary dysplasia  [5] . This is, 
however, going to take a long time, due to the substantial 
number of such products currently still on the market  [1] . 
The extensive use of off-label and unlicensed drugs as well 
as old and widely used medicines will probably remain as 
no real legal pressure has been exerted in this domain and 
the financial incentive for pharmaceutical companies to 
perform clinical studies in children is limited. Thus, the 
role of public funding agencies and academic investiga-
tors is crucial in this field. 
 One example of a drug that has been used for more 
than 40 years and was, until 2006, one of the most com-
monly prescribed drugs in neonatal medicine with only a 
few relatively small and short-term studies supporting its 
use, is caffeine, a methylxanthine and a nonspecific in-
hibitor of adenosine receptors  [6] . It is thanks to the ef-
forts of Barbara Schmidt and the Caffeine for Apnea of 
Prematurity (CAP) Trial Group, together with the Cana-
dian Institutes of Health Research (CIHR) and the Na-
tional Health and Medical Research Council of Australia 
(NHMRC) who funded the trial, that we now have high-
quality and reliable data not only on short-term but also 
long-term outcomes of caffeine use for apnea of prema-
turity  [7, 8] . In 1999, when CAP started patient recruit-
ment, there was reasonable doubt about the safety of caf-
feine in very preterm infants and genuine uncertainty in 
the expert neonatal community whether it would be ben-
eficial in the long term, a situation which describes the 
principle of clinical equipoise  [6] . Fifteen years later, the 
neonatal community can be reasonably sure that the ben-
efits of caffeine treatment for apnea of prematurity out-
weigh the risks, and the story of caffeine in neonatology 
can indeed be considered a success.
 The Discovery of Caffeine 
 Coffee beans have been chewed in the highlands of 
Ethiopia for hundreds of years  [9] . One story of the origin 
of coffee as a beverage is the myth of Kaldi the Ethiopian 
goatherd  [9] . The story goes that Kaldi noticed the stimu-
lating effects of coffee beans when his goats chewed the 
red cherries of a certain bush, which made him try the 
berries himself. Their energizing effect prompted him to 
bring the berries to a holy man in a nearby monastery. 
However, the saint disapproved of their use and threw 
them into the fire. Just afterwards, an enticing aroma 
emerged from the flames. The roasted beans were quick-
ly taken out of the fire, pulverized and added to hot water, 
leading to the world’s first cup of coffee  [9] . While the 
story of Kaldi is a myth, it is in fact likely that Ethiopians 
were the first to have recognized the stimulating effect of 
the coffee plant, a member of the Rubiaceae family  [9] . 
According to this theory, which takes its support from 
traditional tales and current practice, tribesmen collected 
the ripe coffee berries from wild bushes, crushed them 
with stone mortars and mixed them with animal fat, 
forming small balls that they carried with them in military 
conflicts  [9] . 
 Nevertheless, the most popular formulation of caf-
feine has been, and still is, as a beverage, including tea 
and coffee. Tea has been consumed for thousands of 
years in Asia. The Taoists and Zen Buddhists relied on 
the caffeine in tea for their meditations. The notion that 
tea is an indispensable ingredient of the elixir of life has 
been ascribed to Lao-tzu, the founder of Taoism, in a 
Chinese text of the 1st century BC  [9] . Later, his follow-
ers, the Taoist alchemists, called it the ‘froth of the liquid 
jade’  [9] . Bodhidharma, who founded the school of Bud-
dhism based on meditation which later became Zen Bud-
dhism is said to have been involved in the introduction 
of tea to China  [9] . One T’ang dynasty story tells that 
Bodhidharma cut off his own eyelids in anger for having 
fallen asleep after nine continuous years of meditation. 
The eyelids fell to the ground and took root, transform-
ing into tea bushes that would sustain meditations for-
ever after  [9] .
 In the 15th century, Sufis may have been the first to use 
caffeine expressly for its pharmacological effects. Sufism 
requires of its followers that they perform a remembrance 
ritual to the glory of God. Before performing this ritual, 
coffee was shared by the Sufis in a ceremony described by 
Jaziri Avion  [9, 10] :
 They drank it every Monday and Friday eve, putting it in a large 
vessel made of red clay. Their leader ladled it out with a small dipper 
and gave it to them to drink, passing it to the right, while they re-
cited one of their usual formulas, ‘There is no God, but God, the 
Master, the Clear Reality’ .  
 From the example of the Sufi conclaves, the coffee-
house was born. By 1510, coffee had spread from the 
monasteries of the Yemen into general use in Islamic 
capitals such as Cairo and Mecca  [9] . At one point, Mec-
ca’s police-chief banned the consumption of coffee, but 
soon after, the Sultan of Cairo, a coffee-drinker himself, 
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reversed the ban  [9] . In 1555, coffee and the coffeehouse 
were brought to Constantinople by Hakam and Shams, 
Syrian businessmen from Aleppo and Damascus, re-
spectively, and to this day, coffee and coffeehouses are 
very popular in Turkey and its neighboring countries  [9, 
10] .
 An encounter between a scientist and a poet resulted 
in isolated caffeine first being revealed to the world. The 
discovery was made by a young physician, Friedlieb Fer-
dinand Runge, in 1819, after an encounter with the 
70-year-old Johann Wolfgang von Goethe, one of the 
world’s greatest poets  [9, 11] . Runge was studying under 
the chemist Döbereiner, who brought one of Runge’s 
main discoveries to Goethe’s attention: the potential of 
Belladonna extract to dilate the pupil  [9] . Goethe, who 
was not only a poet but also an amateur scientist, invited 
Runge to visit him to demonstrate this phenomenon. 
Runge accepted the invitation and performed the experi-
ment by placing a few drops of Belladonna extract into 
the eye of a cat that Runge had brought with him  [9] . 
Goethe was intrigued and presented Runge with a box of 
rare Arabian mocha coffee beans, inviting him to perform 
an analysis of the contents. This led to the isolation of the 
world’s first sample of pure caffeine  [9] .
 How Does Caffeine Work? 
 Caffeine is a methylxanthine and acts as a nonspecific 
inhibitor of 2 of the 4 known adenosine receptors  [12] . 
The receptors that transduce adenosine action are the 
A1, A2a, A2b and A3 adenosine receptors  [6] . Adenosine 
is a purine nucleoside that is produced naturally in hu-
man tissues, including the brain  [11] . Few signaling mol-
ecules have the potential to influence the developing hu-
man organism like the nucleoside adenosine  [13] . Aden-
osine levels increase rapidly with inflammation  [13] . 
Two known scenarios that cause an imbalance between 
adenosine synthesis and adenosine breakdown are hyp-
oxia and ischemia  [12] . The extracellular concentration 
of adenosine rises in the brain when energy demand out-
strips energy supply and brain cells are at risk of dying 
 [11] . In the postnatal period, A1 adenosine receptor ac-
tivation may contribute to the injury of white matter in 
the preterm infant by altering oligodendrocyte develop-
ment  [13] . Adenosine slows things down in order to pre-
serve precious energy  [11] . In models of perinatal brain 
injury, caffeine is neuroprotective against periventricular 
white matter injury and hypoxic-ischemic encephalopa-
thy  [13] .
 Caffeine as a Treatment for Apnea of Prematurity 
 The CAP trial was launched to resolve the uncertainty 
about the long-term effects of caffeine used as a respira-
tory stimulant in preterm infants  [11] . This international, 
multicenter, placebo-controlled randomized trial was de-
signed to determine whether survival without neurode-
velopmental disability at a corrected age of 18 months is 
improved if apnea of prematurity is managed without 
methylxanthines in infants at a high risk of apneic attacks 
 [7] . CAP was one of the largest neonatal trials conducted 
and was deliberately kept simple and pragmatic in order 
to allow for maximum generalizability and applicability 
under real-world conditions. Infants with a birth weight 
of 500–1,250 g were enrolled during the first 10 days of 
life if their clinicians considered them to be candidates for 
methylxanthine therapy  [7] ; 2,006 infants were randomly 
assigned to receive either caffeine or placebo. Following 
the recommendation of the external safety monitoring 
committee, the protocol specified secondary short-term 
outcomes were published before the complete ascertain-
ment and publication of the primary outcome  [7] . The 
major findings for the secondary short-term outcomes 
included a reduced incidence of bronchopulmonary dys-
plasia (36% with caffeine and 47% with placebo; OR 0.63 
and 95% CI 0.52–0.76; p < 0.001). Caffeine also reduced 
weight gain for the first 3 weeks after the start of therapy. 
Head circumference was not affected and the rates of 
death, ultrasonographic signs of brain injury and necro-
tizing enterocolitis were similar in the caffeine and pla-
cebo groups  [7] .
 In 2007, the primary outcome data of CAP were pub-
lished  [8] . The primary outcome was a composite of 
death, cerebral palsy, cognitive delay (defined as a Mental 
Developmental Index score of <85 on the Bayley Scales of 
Infant Development II), hearing loss requiring amplifica-
tion or bilateral blindness at a corrected age of 18–21 
months  [8] . Of the infants for whom adequate data on the 
primary outcome were available, 377 of 937 (40.2%) as-
signed to caffeine died or survived with a neurodevelop-
mental disability and 431 of 932 (46.2%) assigned to pla-
cebo died or survived with neurodevelopmental disabil-
ity (OR 0.77, 95% CI 0.64–0.93; p = 0.008)  [8] . 
 When 1,640 (84.9%) of the 1,932 study children who 
were eligible were assessed at the age of 5 years to deter-
mine whether neonatal caffeine therapy has lasting ben-
efits or newly apparent risks at early school age, the dif-
ference between the caffeine and placebo groups was no 
longer statistically significant  [14] . The outcome assessed 
at this 5-year follow-up was a combined one of death or 
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survival to 5 years with 1 or more of the following: motor 
impairment (defined as a Gross Motor Function Classifi-
cation System level of 3–5), cognitive impairment (de-
fined as a Full-Scale IQ <70 on the Wechsler Preschool 
and Primary Scale of Intelligence III), behavioral prob-
lems, poor general health, severe hearing loss and bilat-
eral blindness  [14] .
 Economic Aspects of Caffeine for Apnea of 
Prematurity 
 Caffeine not only reduces the rate of bronchopulmo-
nary dysplasia and improves the rate of survival without 
neurodevelopmental disability at 18–21 months in in-
fants with a birth weight of 500–1,250 g, it is also a cost-
saving therapy compared with placebo  [15] . In a retro-
spective economic evaluation alongside the CAP study 
using individual-patient data, Dukhovny et al.  [15] found 
that the probability of caffeine being not only effective but 
also cost-saving was >99%. This effect was, in large part, 
attributed to the reduced number of days on positive 
pressure ventilation. In their analysis, the authors includ-
ed the direct medical costs for the insurance payer or the 
hospital, but excluded the costs for parents and society. 
Their cost assumptions were based on Canadian prices to 
resource tallies from all trial participants and, from to-
day’s perspective, included a relatively low cost of caffeine 
citrate (CAD 0.21/mg). Since then, prices for caffeine 
have risen substantially as it is now a licensed product for 
the treatment of apnea of prematurity in some countries. 
However, the results of the economic evaluation were ro-
bust to a substantial increase in the individual resource 
items, including the price of caffeine citrate. Increasing 
the price of caffeine citrate 100-fold from CAD 0.1, caf-
feine still remained not only effective but also cost-saving 
 [15] .
 Caffeine as Prophylaxis for Apnea of Prematurity 
 The eligibility criteria of the CAP study were deliber-
ately broad and pragmatic. Infants could be randomized 
in the first 10 days of life when caregivers considered 
them to be candidates for methylxanthine therapy  [7] . 
The most frequent indication reported in the CAP study 
was the treatment of documented apnea (41.5%), fol-
lowed by the facilitation of removal of an endotracheal 
tube (36%). Only 22.5% of the neonatologists in the trial 
started caffeine for the prevention of apnea  [7] . Thus, the 
findings of the CAP study cannot automatically be ex-
trapolated to a prophylactic indication, even if it is reas-
suring that in a post hoc subgroup analysis performed for 
the indication for starting on the study drug, little evi-
dence of heterogeneity of treatment effect for any out-
come assessed was found  [16] . Post hoc subgroup analy-
ses also suggest evidence of variable beneficial effects of 
caffeine. Infants receiving respiratory support appeared 
to derive more neurodevelopmental benefits from caf-
feine than infants not receiving support  [16] . In addition, 
earlier initiation of caffeine (<3 days) may be associated 
with a greater reduction in time on ventilation than later 
initiation (>3 days)  [16] . However, it is important to 
stress that although effect sizes and directions of effect of 
caffeine varied in the subgroups, there was no evidence of 
harm that reached statistical significance  [16] . When ap-
plying the CAP study findings to individual patients, one 
should keep the subgroup analyses results in mind. From 
a methodological point of view, however, caution should 
be exercised in the interpretation of these subgroups. 
There was no stratification for clinical indication, and the 
time of starting on the study drug and level of respiratory 
support were not recorded in the CAP study. Further-
more, the sample size was not calculated based on these 
subgroups  [16] .
 As pointed out above, the findings of the CAP study 
cannot automatically be extrapolated to an exclusively 
prophylactic indication or to all preterm infants, regard-
less of their gestational age and risk for apnea of pre-
maturity. However, in a recent cross-sectional survey of 
neonatologists in Thailand, Lebanon, Australia and a
representative sample in the USA with regard to the man-
agement of apnea of prematurity with a response rate of 
50%, the use of prophylactic methylxanthine was very com-
mon (62%) among neonatologists at all 4 locations  [17] .
 Tribute to Barbara Schmidt 
 Certain names come to mind when considering the 
people who made the investigation of caffeine therapy for 
apnea of prematurity a success story. Kuzemko and Paala 
 [18]  published the first report of methylxanthine use for 
apnea of prematurity in 1973. Aranda et al.  [19] reported 
the first use of caffeine therapy for apnea in the English 
biomedical literature. When it comes to controlled clini-
cal trials, one name clearly stands out: Barbara Schmidt. 
An encounter between two people with different profes-
sional backgrounds, Runge the scientist and Goethe the 
poet, resulted in isolated caffeine first being revealed to 
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the world, but a clinical trial designed chiefly by one per-
son, Barbara Schmidt, combining her expertise in clinical 
epidemiology and neonatology, is what demonstrated 
clearly the important benefits of caffeine therapy for ap-
nea of prematurity. Currently a Professor of Pediatrics 
and a Senior Scholar in the Center for Clinical Epidemiol-
ogy and Biostatistics at the School of Medicine, Univer-
sity of Pennsylvania, she is also a staff neonatologist in the 
Division of Neonatology at the Children’s Hospital of 
Philadelphia and the University of Pennsylvania Health 
System. Barbara Schmidt’s research focuses on collabora-
tive neonatal randomized trials that have clinically im-
portant, long-term outcomes, not only for caffeine but 
also for other drugs such as indomethacin  [20] . When 
neonatologists are asked what the main research findings 
during the past years are that have changed their ap-
proach to clinical practice, many cite Barbara Schmidt’s 
caffeine (CAP) study. This study has contributed sub-
stantially to the fact that caffeine for the treatment of ap-
nea of prematurity can be considered a great neonatal 
success story  [21] .
 Disclosure Statement 
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